1. HIV/HCV Co-Infection Case

2. Disclosures

6. Treatment History

7. Laboratory Values

8. SVR in HIV/HCV Pts According to IL28B

9. Factors Associated with SVR in HIV HCV Treated Pts.

10. IL-28B and DAA

11. Laboratory Values

12. Any other issues that need to be addressed before treatment?

13. Insulin Resistance Influences Response to Treatment with PegIFN/RBV in HIV/HCV Co-Infected Patients

14. Insulin Resistance Influences Response to Re-Treatment with PegIFN/RBV in HIV/HCV Co-Infected Patients

15. Multi-variable Analysis Outcome = SVR

16. Does Vitamin D Play a Role?

17. Does Vitamin D Play a Role?

19. June 2011

20. What do you recommend to this HIV-HCV cirrhotic patient?

21. Is the patient’s HIV regimen compatible with DAA?

22. DAA and co-infected patients

23. Telaprevir and co-infected: Study 110

24. Telaprevir and co-infected: Study 110

25. Boceprevir and co-infected

26. Boceprevir and co-infected

27. Pharmacokinetic interactions

28. Summer 2011

29. HCV viral load

30. CBC

31. Cytopenias and DAA

32. What would you recommend?

33. Growth factors and hepatitis C treatment

34. Growth factors and hepatitis C treatment

35. EPO

36. G-CSF

37. Thrombopoietic agents

38. CBC

39. January 2012

40. RGT

41. Telaprevir response guided therapy (RGT)

42. February 13th 2012